Importantly, the study provides strong evidence of differential effects of carnitines on uterine PCOS features: LC-ALC alleviates PCOS tissue alterations and molecular damage, while the addition of PLC protects against oxidative damage with tissue specificity but exhibits greater efficacy in preventing fibrosis, mitochondrial damage and maintaining SIRT1 homeostasis. Here, SIRT1 is linked to polycystic ovary syndrome.